NO801443L - Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kultur - Google Patents
Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kulturInfo
- Publication number
- NO801443L NO801443L NO801443A NO801443A NO801443L NO 801443 L NO801443 L NO 801443L NO 801443 A NO801443 A NO 801443A NO 801443 A NO801443 A NO 801443A NO 801443 L NO801443 L NO 801443L
- Authority
- NO
- Norway
- Prior art keywords
- virus
- cell culture
- influenza
- cells
- trypsin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 59
- 238000004113 cell culture Methods 0.000 title claims description 37
- 238000004519 manufacturing process Methods 0.000 title claims description 33
- 239000007788 liquid Substances 0.000 title claims description 28
- 241000700605 Viruses Species 0.000 claims description 102
- 210000004027 cell Anatomy 0.000 claims description 66
- 241000712461 unidentified influenza virus Species 0.000 claims description 56
- 229960005486 vaccine Drugs 0.000 claims description 41
- 108090000631 Trypsin Proteins 0.000 claims description 35
- 102000004142 Trypsin Human genes 0.000 claims description 35
- 239000012588 trypsin Substances 0.000 claims description 34
- 241000283073 Equus caballus Species 0.000 claims description 28
- 206010022000 influenza Diseases 0.000 claims description 28
- 229960001322 trypsin Drugs 0.000 claims description 26
- 102000035195 Peptidases Human genes 0.000 claims description 22
- 108091005804 Peptidases Proteins 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 239000004365 Protease Substances 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- 210000003292 kidney cell Anatomy 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 229960003971 influenza vaccine Drugs 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 239000002356 single layer Substances 0.000 claims description 6
- 241000282465 Canis Species 0.000 claims description 5
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- 241000282898 Sus scrofa Species 0.000 claims description 5
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 4
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 4
- 108010019160 Pancreatin Proteins 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 108090000284 Pepsin A Proteins 0.000 claims description 4
- 102000057297 Pepsin A Human genes 0.000 claims description 4
- 229940055695 pancreatin Drugs 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- 229940111202 pepsin Drugs 0.000 claims description 4
- 244000144977 poultry Species 0.000 claims description 4
- 108090000317 Chymotrypsin Proteins 0.000 claims description 3
- 108010059712 Pronase Proteins 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- -1 alum Chemical compound 0.000 claims description 3
- 229960002376 chymotrypsin Drugs 0.000 claims description 3
- 229940037003 alum Drugs 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940124873 Influenza virus vaccine Drugs 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 206010011224 Cough Diseases 0.000 description 10
- 235000013601 eggs Nutrition 0.000 description 10
- 235000019419 proteases Nutrition 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241000283086 Equidae Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 229930182816 L-glutamine Natural products 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000008121 dextrose Substances 0.000 description 6
- 239000003797 essential amino acid Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 3
- 239000012499 inoculation medium Substances 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940049018 mycostatin Drugs 0.000 description 3
- 229940053050 neomycin sulfate Drugs 0.000 description 3
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000012832 cell culture technique Methods 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 238000012808 pre-inoculation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3923679A | 1979-05-15 | 1979-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO801443L true NO801443L (no) | 1980-11-17 |
Family
ID=21904398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO801443A NO801443L (no) | 1979-05-15 | 1980-05-14 | Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kultur |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0019218B2 (ja) |
| JP (1) | JPS55153723A (ja) |
| AR (1) | AR220838A1 (ja) |
| AT (1) | ATE16454T1 (ja) |
| AU (1) | AU535804B2 (ja) |
| CA (1) | CA1122527A (ja) |
| DE (1) | DE3071225D1 (ja) |
| DK (1) | DK154749C (ja) |
| ES (1) | ES491517A0 (ja) |
| IL (1) | IL60063A0 (ja) |
| NO (1) | NO801443L (ja) |
| RO (1) | RO79525B (ja) |
| YU (1) | YU41923B (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
| US5753489A (en) * | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
| US5698433A (en) * | 1994-11-10 | 1997-12-16 | Immuno Ag | Method for producing influenza virus and vaccine |
| EP1213030B1 (en) * | 1994-11-10 | 2009-04-22 | Baxter Healthcare SA | Method for producing biologicals in protein-free culture |
| WO1996015232A1 (en) * | 1994-11-16 | 1996-05-23 | St. Jude Children's Research Hospital | Novel replication process |
| DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| US6830917B2 (en) | 2001-12-10 | 2004-12-14 | Baxter Healthcare S.A. | Method of isolation and purification of trypsin from pronase protease and use thereof |
| EP1807116B1 (en) | 2004-11-03 | 2015-05-06 | Novartis Vaccines and Diagnostics, Inc. | Influenza vaccination |
| EP2022849A4 (en) | 2006-05-11 | 2010-10-06 | Chemo Sero Therapeut Res Inst | METHOD FOR PROLIFERATION OF INFLUENZA VIRUS |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| TW201012930A (en) * | 2008-06-16 | 2010-04-01 | Intervet Int Bv | Method of replicating viruses in suspension |
| CA2751379C (en) | 2009-02-10 | 2018-06-12 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2262962B1 (ja) * | 1974-03-05 | 1977-11-04 | Science Union & Cie |
-
1980
- 1980-04-22 CA CA350,366A patent/CA1122527A/en not_active Expired
- 1980-04-30 AR AR280860A patent/AR220838A1/es active
- 1980-05-08 DE DE8080102525T patent/DE3071225D1/de not_active Expired
- 1980-05-08 EP EP80102525A patent/EP0019218B2/de not_active Expired - Lifetime
- 1980-05-08 AT AT80102525T patent/ATE16454T1/de not_active IP Right Cessation
- 1980-05-09 AU AU58244/80A patent/AU535804B2/en not_active Expired
- 1980-05-13 YU YU1265/80A patent/YU41923B/xx unknown
- 1980-05-13 RO RO101109A patent/RO79525B/ro unknown
- 1980-05-13 IL IL60063A patent/IL60063A0/xx unknown
- 1980-05-13 JP JP6235780A patent/JPS55153723A/ja active Granted
- 1980-05-14 NO NO801443A patent/NO801443L/no unknown
- 1980-05-14 ES ES491517A patent/ES491517A0/es active Granted
- 1980-05-14 DK DK212580A patent/DK154749C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3071225D1 (en) | 1985-12-19 |
| DK154749B (da) | 1988-12-19 |
| AU535804B2 (en) | 1984-04-05 |
| DK154749C (da) | 1989-05-16 |
| DK212580A (da) | 1980-11-16 |
| EP0019218B1 (de) | 1985-11-13 |
| RO79525B (ro) | 1984-09-30 |
| ES8104405A1 (es) | 1981-04-01 |
| ES491517A0 (es) | 1981-04-01 |
| EP0019218A3 (en) | 1981-03-25 |
| JPH0124769B2 (ja) | 1989-05-15 |
| EP0019218A2 (de) | 1980-11-26 |
| AR220838A1 (es) | 1980-11-28 |
| CA1122527A (en) | 1982-04-27 |
| YU41923B (en) | 1988-02-29 |
| IL60063A0 (en) | 1980-07-31 |
| RO79525A (ro) | 1984-07-17 |
| EP0019218B2 (de) | 1995-03-01 |
| JPS55153723A (en) | 1980-11-29 |
| ATE16454T1 (de) | 1985-11-15 |
| AU5824480A (en) | 1980-11-20 |
| YU126580A (en) | 1983-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4500513A (en) | Influenza vaccine production in liquid cell culture | |
| CA2250078C (en) | Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
| US6656720B2 (en) | Animal cells and processes for the replication of influenza viruses | |
| NO801443L (no) | Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kultur | |
| CZ105098A3 (cs) | Vakcína proti chřipce a způsob její přípravy | |
| WO2002024876A2 (en) | Live influenza vaccine and method of manufacture | |
| AU2002223560A1 (en) | Live influenza vaccine and method of manufacture | |
| US4338296A (en) | Influenza virus and process of producing a vaccine therefrom | |
| US3950512A (en) | Animal vaccines | |
| US4302444A (en) | Vaccines for immunizing egg-laying birds against Egg Drop disease, preparation of said vaccines, and method of use of said vaccines | |
| USRE33164E (en) | Influenza vaccine production in liquid cell culture | |
| US3080291A (en) | Serial passage of distemper virus in tissue cultures of chick embryo and canine tissue and vaccine therefrom | |
| HU181993B (en) | Process for producing weakened stock of virus of peritonitis | |
| US3961046A (en) | Mumps vaccine and preparation thereof | |
| RU2126268C1 (ru) | Вакцина для профилактики инфекционного заболевания сумки у цыплят, лиофилизированная вирусная композиция, способ защиты цыплят от этого заболевания и способ получения живой вакцины | |
| US4351827A (en) | Novel polyvalent virus vaccine | |
| CA1152895A (en) | Process for the preparation of novel influenza virus strains and influenza virus vaccines containing them | |
| EP0009277B1 (en) | Combined vaccine active against newcastle disease and egg production drop caused by adeno-like viruses, process for preparing it, adeno-like and newcastle disease virus strains | |
| US3962423A (en) | Live influenza type B virus vaccines and preparation thereof | |
| KR101093510B1 (ko) | 돼지 인플루엔자 예방을 위한 세포 기원 불활화 백신 및 그의 제조방법 | |
| KR830002615B1 (ko) | 세포배양액내에서 인플루엔자 왁진의 제조방법 | |
| US3629396A (en) | Avian encephalomyelitis vaccine | |
| US3432391A (en) | Attenuated infectious canine hepatitis live virus vaccine and method of producing same | |
| CA1216234A (en) | Preparation of modified strains of bovine diarrhoea virus and vaccines containing them | |
| US3178351A (en) | Vaccine |